Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
Released: Feb 11, 2016
Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.
